Fig. 2

Kaplan-Meier estimates of DFS and OS in the whole population. a. The estimated 5-year DFS rate was 89.7% for HER2- patients and 90.2% for HER2+ patients treated with trastuzumab (P = 0.185). HER2-pos-T was associated with significantly better DFS (P < 0.001) after adjusting neo-adjuvant therapy, breast surgery, tumor size, ALN status, histological grade, LVI, ER level, PR level, Ki-67 level, radiotherapy, chemotherapy, and endocrine therapy. b. The estimated 5-year OS rate was 96.0% in the HER2-neg group and 96.3% in the HER2-pos-T group (P = 0.133). HER2-pos-T was associated with significantly better OS (P = 0.037) after adjusting menstrual status, neo-adjuvant therapy, breast surgery, tumor size, ALN status, histological grade, LVI, ER level, PR level, Ki-67 level, radiotherapy, and endocrine therapy